We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Surmodics (SRDX) Down 2.7% Since the Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Surmodics, Inc. (SRDX - Free Report) . Shares have lost about 2.7% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Surmodics, Inc. (SRDX - Free Report) reported earnings of $0.19 per share in the first-quarter of fiscal 2017 (ended Dec 31, 2016), surpassing the Zacks Consensus Estimate of $0.09. Reported earnings were, however, lower than the year-ago figure of $0.38.
Revenues in the quarter increased 7.4% to $17.8 million. Reported revenues were also above the Zacks Consensus Estimate of $16 million.
Quarter in Detail
Surmodics reports revenues in two segments – In Vitro Diagnostics (IVD) and Medical Device.
Medical Device
In the reported quarter sales surged 12.3% to $13.8 million. The growth came from higher product sales, royalties, research, development and other revenue.
In Vitro Diagnostics (IVD)
In the reported quarter sales fell 6.8% to $4.0 million. The downside came from lower sales in several product categories as well as a decline from a significant microarray customer that had been acquired by one of the company’s competitors.
Balance Sheet and Cash Flow
As of Dec 31, 2016, the company had $17.7 million of Cash and cash equivalents versus $25.0 million at the end of the sequential quarter. Surmodics generated cash from operating activities of $2.0 million in the first quarter of fiscal 2017. Capital expenditures totaled $1.5 million in the reported quarter.
Outlook
Surmodics expects fiscal 2017 earnings in the range of $0.18 to $0.33 per share as compared with prior guidance of $0.15 to $0.35 per share. Meanwhile, revenues are expected in the range of $64.0 million to $68.0 million, up from a previous range of $63.0 million to $67.0 million.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
At this time, Surmodics' stock has a nice Growth Score of 'B', however its Momentum is lagging a bit with an 'C'. Following the exact same course, the stock was allocated a grade of 'C' on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'B'. If you aren't focused on one strategy, this score is the one you should be interested in.
Based on our scores, the stock is more suitable for growth investors than for value investors.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Surmodics (SRDX) Down 2.7% Since the Last Earnings Report?
A month has gone by since the last earnings report for Surmodics, Inc. (SRDX - Free Report) . Shares have lost about 2.7% in that time frame, underperforming the market.
Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
SurModics (SRDX - Free Report) Beats Q1 Earnings & Revenues Estimates
Surmodics, Inc. (SRDX - Free Report) reported earnings of $0.19 per share in the first-quarter of fiscal 2017 (ended Dec 31, 2016), surpassing the Zacks Consensus Estimate of $0.09. Reported earnings were, however, lower than the year-ago figure of $0.38.
Revenues in the quarter increased 7.4% to $17.8 million. Reported revenues were also above the Zacks Consensus Estimate of $16 million.
Quarter in Detail
Surmodics reports revenues in two segments – In Vitro Diagnostics (IVD) and Medical Device.
Medical Device
In the reported quarter sales surged 12.3% to $13.8 million. The growth came from higher product sales, royalties, research, development and other revenue.
In Vitro Diagnostics (IVD)
In the reported quarter sales fell 6.8% to $4.0 million. The downside came from lower sales in several product categories as well as a decline from a significant microarray customer that had been acquired by one of the company’s competitors.
Balance Sheet and Cash Flow
As of Dec 31, 2016, the company had $17.7 million of Cash and cash equivalents versus $25.0 million at the end of the sequential quarter. Surmodics generated cash from operating activities of $2.0 million in the first quarter of fiscal 2017. Capital expenditures totaled $1.5 million in the reported quarter.
Outlook
Surmodics expects fiscal 2017 earnings in the range of $0.18 to $0.33 per share as compared with prior guidance of $0.15 to $0.35 per share. Meanwhile, revenues are expected in the range of $64.0 million to $68.0 million, up from a previous range of $63.0 million to $67.0 million.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last one month period as none of them issued any earnings estimate revisions.
Surmodics, Inc. Price and Consensus
Surmodics, Inc. Price and Consensus | Surmodics, Inc. Quote
VGM Scores
At this time, Surmodics' stock has a nice Growth Score of 'B', however its Momentum is lagging a bit with an 'C'. Following the exact same course, the stock was allocated a grade of 'C' on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of 'B'. If you aren't focused on one strategy, this score is the one you should be interested in.
Based on our scores, the stock is more suitable for growth investors than for value investors.
Outlook
The stock has a Zacks Rank #3 (Hold). We are expecting an inline return from the stock in the next few months.